Evidence mapPaperPMID 42250040Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026

Identification of Patient Clusters with Distinct Disease Progression Patterns Utilizing a Nationwide Finnish Population with Type 2 Diabetes.

Kim Nygård, Riitta Ryhänen, Aaron Kortteenniemi, Kajsa Järvinen, Aino Vesikansa, Juha Mehtälä, Mirkka Koivusalo, Annakaisa Tirronen, Eralda Asllanaj, Jarmo Kaukua and 2 more

Abstract read
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kim NygårdCity of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0009-0006-3811-569X
Riitta RyhänenWell-Being Service County of Kymenlaakso, Kouvola, Finland.
Aaron KortteenniemiDepartment of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-3042-8257
Kajsa JärvinenPihlajalinna, Helsinki, Finland.
Aino VesikansaMedEngine Oy, Helsinki, Finland. aino.vesikansa@medengine.fi.ORCID http://orcid.org/0000-0002-6386-9956
Juha MehtäläMedEngine Oy, Helsinki, Finland.ORCID http://orcid.org/0000-0003-4088-8561
Mirkka KoivusaloMedEngine Oy, Helsinki, Finland.
Annakaisa TirronenBoehringer Ingelheim Ky, Helsinki, Finland.
Eralda AsllanajBoehringer Ingelheim B.V., Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-7329-6194
Jarmo KaukuaBoehringer Ingelheim Ky, Helsinki, Finland.
Sami PakarinenDepartment of Cardiology, Helsinki University Hospital, Helsinki, Finland.ORCID http://orcid.org/0000-0002-5904-5954
Juha TuominenHelsinki University, Helsinki, Finland.ORCID http://orcid.org/0000-0003-2727-8849

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVariability in the clinical presentation of patients with type 2 diabetes (T2D) is high and underlines the need for more personalized patient care. This nationwide study aimed to describe characteristics, treatment patterns, and disease progression of Finnish patients with T2D (N = 302,987), and to identify patient clusters with distinct progression patterns based on the occurrence of diabetes-related complications.

methodsThe study included all adult patients with incident T2D in Finland between 2010 and 2019. Data were collected from national health and social care registers, data lakes, and a private healthcare provider between 1996 and 2021. Patient clusters were identified based on disease progression, defined by the occurrence of 22 pre-defined end-points, using likelihood-based growth mixture modeling.

resultsFive patient clusters with stable (C1; n = 133,951), mild (C2; n = 52,819), moderate (C3, n = 43,488), rapid (C4; n = 10,159), and extremely rapid progression (C5; n = 1973) were identified. The mean number of end-point complications per patient at baseline ranged from 0.2 to 2.3 across clusters and remained stable in C1-C3 over the first 5 years. In C5, the number increased to 5.5 and 7.2 during the first and third follow-up years, respectively, with a similar but more modest annual increase observed in C4. Cardiovascular complications increased more rapidly in C5 and C4 than C1-C3. T2D medication use was more common in milder clusters, whereas 31.4% and 48.2% of patients in C4 and C5, respectively, had no T2D medication. The rate of certain infections and values of creatinine, hemoglobin, and erythrocytes, increased with cluster severity.

conclusionsDiagnosis of several other new conditions, particularly cardiovascular complications, at or soon after incident T2D diagnosis predicts poor prognosis. The results further support a comprehensive approach in diabetes care, including evaluation and treatment of cardiovascular diseases alongside glycemic control.

Indexed as

ClusteringReal-world evidenceRegister studyRWET2DType 2 diabetes

Identifiers

PMID42250040
PMCPMC13388581

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.